Unique ID issued by UMIN | UMIN000028605 |
---|---|
Receipt number | R000032727 |
Scientific Title | A retrospective study for ALK positive Lung Cancer - The Clinical Benefits of Sequential Therapy using Crizotinib followed by Alectinib in Clinical Practice: A Multicenter Retrospective Study. - (WJOG9516L) |
Date of disclosure of the study information | 2017/08/09 |
Last modified on | 2021/10/08 17:09:59 |
A retrospective study for ALK positive Lung Cancer
- The Clinical Benefits of Sequential Therapy using Crizotinib followed by Alectinib in Clinical Practice: A Multicenter Retrospective Study. - (WJOG9516L)
A retrospective study for ALK positive Lung Cancer
A retrospective study for ALK positive Lung Cancer
- The Clinical Benefits of Sequential Therapy using Crizotinib followed by Alectinib in Clinical Practice: A Multicenter Retrospective Study. - (WJOG9516L)
A retrospective study for ALK positive Lung Cancer
Japan |
Non-small-cell lung cancer (NSCLC)
Pneumology | Hematology and clinical oncology |
Malignancy
NO
The aim of this study is to clarify the background of ALK rearrangement NSCLC patients, treatment and outcome, efficacy and safety of ALK inhibitors, and prognosis in clinical practice.
Safety,Efficacy
Others
Not applicable
Combined time-treatment-failure (TTF) of crizotinib and alectinib
Overall survival (OS)
Time to treatment failure (TTF)
Progression-free survival (PFS)
Combined PFS
Objective response rate (ORR)
TTF of chemotherapy
Observational
Not applicable |
Not applicable |
Male and Female
1) Confirmed diagnosis with NSCLC pathologically.
2) Confirmed diagnosis with ALK rearranged by molecular analysis.
3) Received crizotinib and/or alectinib therapy between May 1, 2012 and Dec 31, 2016.
No prior exposure of ceritinib before crizotinib or alectinib, regardless of clinical trial or practice.
700
1st name | |
Middle name | |
Last name | Kentaro Ito |
Matsusaka Municipal Hospital
Department of Respiratory Medicine
1550, Tonomachi, Matsusaka city, Mie, Japan
0598-23-1515
kentarou_i_0214@yahoo.co.jp
1st name | |
Middle name | |
Last name | Shinichiro Nakamura |
West Japan Oncology Group
WJOG datacenter
Namba Plaza Bldg. 304-1-5-7, Motomachi Naniwa-ku, Osaka 556-0016 JAPAN
06-6633-7400
datacenter@wjog.jp
West Japan Oncology Group
none
Self funding
NO
2017 | Year | 08 | Month | 09 | Day |
Unpublished
Completed
2017 | Year | 08 | Month | 06 | Day |
2017 | Year | 08 | Month | 06 | Day |
2017 | Year | 09 | Month | 01 | Day |
2019 | Year | 03 | Month | 09 | Day |
TTF, OS, and PFS will be calculated and compared retrospectively between treatment groups with using Cox hazard model or propensity scoring.
2017 | Year | 08 | Month | 09 | Day |
2021 | Year | 10 | Month | 08 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000032727
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |